PE78899A1 - Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona - Google Patents

Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Info

Publication number
PE78899A1
PE78899A1 PE1998000466A PE00046698A PE78899A1 PE 78899 A1 PE78899 A1 PE 78899A1 PE 1998000466 A PE1998000466 A PE 1998000466A PE 00046698 A PE00046698 A PE 00046698A PE 78899 A1 PE78899 A1 PE 78899A1
Authority
PE
Peru
Prior art keywords
piridil
etoxi
bencil
diona
thiazolidin
Prior art date
Application number
PE1998000466A
Other languages
English (en)
Inventor
Hamish Ross
Robin Price
Jeffrey Roger Granett
Jaikrishna Patel
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE78899A1 publication Critical patent/PE78899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

CARACTERIZADA PORQUE COMPRENDE UN COMPUESTO 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA DE 2 A 12 mg O COMO UNA SAL DE MALEATO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE LA MEZCLA DEL COMPUESTO CON UN PRIMER VEHICULO, LUEGO MEZCLAR CON UN SEGUNDO VEHICULO. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE EL COMPUESTO, SAL SODICA DE GLICOLATO DE ALMIDON, HIDROXIPROPILMETILCELULOSA 2910, CELULOSA MICRO-CRISTALINA Y LACTOSA MONOHIDRATADA
PE1998000466A 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona PE78899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
PE78899A1 true PE78899A1 (es) 1999-10-22

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000466A PE78899A1 (es) 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1112926C (es)
AP (1) AP1214A (es)
AR (2) AR008198A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2292629C (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR199902963T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA984826B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286423B6 (sk) 1999-04-23 2008-09-05 Smithkline Beecham Plc Polymorfná forma soli 5-[4-[2-(N-metyl-N-2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu s kyselinou maleínovou, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
SK286427B6 (sk) 1999-04-23 2008-09-05 Smithkline Beecham Plc Polymorfná forma soli 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu s kyselinou maleínovu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9603338A (es) * 1994-02-10 1997-03-29 Smithkline Beecham Plc Uso de sensibilizadores a la insulina para tratar enfermedades renales.
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
AU3552697A (en) * 1996-07-12 1998-02-09 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
EA002384B1 (ru) 2002-04-25
AU8215098A (en) 1998-12-21
UY25032A1 (es) 1998-11-26
NO20040738L (no) 2000-02-02
ZA984826B (en) 1999-08-03
AP1214A (en) 2003-10-08
DZ2510A1 (fr) 2003-01-25
AR015120A1 (es) 2001-04-18
ID24264A (id) 2000-07-13
OA11306A (en) 2003-10-22
PL337201A1 (en) 2000-08-14
CA2292629A1 (en) 1998-12-10
CO4940400A1 (es) 2000-07-24
CN1526391A (zh) 2004-09-08
BR9810405A (pt) 2000-08-29
TR199902963T2 (xx) 2000-02-21
SK164899A3 (en) 2000-11-07
CA2292629C (en) 2004-01-06
TR200002790T2 (tr) 2001-11-21
NO995938D0 (no) 1999-12-03
EA199901116A1 (ru) 2000-06-26
MXPA99011322A (es) 2004-12-02
CN1112926C (zh) 2003-07-02
NZ513922A (en) 2001-09-28
GB9711683D0 (en) 1997-08-06
ZA9811572B (en) 1999-07-22
CN1259050A (zh) 2000-07-05
EP0998284A1 (en) 2000-05-10
NO995938L (no) 2000-02-02
KR20010013410A (ko) 2001-02-26
AR008198A1 (es) 1999-12-29
CA2333352A1 (en) 1998-12-10
AP9901696A0 (en) 1999-12-31
BG104048A (bg) 2000-07-31
IL133074A0 (en) 2001-03-19
JP2001521553A (ja) 2001-11-06
CN1430959A (zh) 2003-07-23
HUP0004070A3 (en) 2002-03-28
HUP0004070A2 (hu) 2002-02-28
WO1998055122A1 (en) 1998-12-10
TW570797B (en) 2004-01-11
NZ523725A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
PE78899A1 (es) Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
TR200001880T2 (tr) İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.
MA30598B1 (fr) Composition pharmaceutique contenant un acide tetrahydrofolique.
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
DE69803750D1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
JO2239B1 (en) Method for preparing benzothophen derivatives
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
WO2007011878A8 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
BR0111868A (pt) Composições farmacêuticas
PE20000329A1 (es) Derivados de indol y composiciones farmaceuticas que los contienen
ES2188766T3 (es) Composicion farmaceutica que contiene lamotrigina.
EA200601144A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
TR200002543T2 (tr) Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
ID27649A (id) Proses pembuatan kertas
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
PE61699A1 (es) Composicion farmaceutica de lamivudina
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
AR051727A1 (es) Formulacion oral de liberacion inmediata de una sustancia activa poco soluble en agua

Legal Events

Date Code Title Description
FC Refusal